After a consultation with one of the physicians at Juventas, we discussed peptide therapy, and specifically BPC-157, a peptide known for its regenerative and anti-inflammatory properties
For people with chronic inflammation, fatigue, gut issues, or neurological symptoms, diet alone may not be enough
Graduation from cautious introductions to more confident usage is key
because rigorously controlled human safety data specific to the TB-500 fragment does not exist, its longer-term risk profile, including possible immune reactions, remains unknown Evidence snapshot: Evidence for TB-500 itself is preclinical, drawn mainly from cell-culture and animal studies (a 1999 rat wound-healing study and later rodent cardiac- and tendon-injury models), with a 2026 scoping review describing the musculoskeletal literature on thymosin beta-4 and TB-500 as sparse and largely preclinical